Chronic Kidney Disease: Global Burden, Risk Stratification, and Multimodal Management
Chronic Kidney Disease (CKD)—defined as kidney damage or GFR <60 mL/min/1.73m² for ≥3 months—affects ∼10% of adults worldwide. It's a progressive, often silent condition that exponentially increases cardiovascular risk and healthcare costs.
Epidemiology and Risk Stratification
| Risk Factor | Population Attributable Risk | Mechanism |
|---|---|---|
| Diabetes | ∼40% of ESRD | Hyperglycemia → glomerular hyperfiltration → sclerosis |
| Hypertension | ∼25% of ESRD | Vascular nephrosclerosis; glomerular pressure |
| Age >60 | Prevalence 38% (60–69), 47% (≥70) | Nephron loss, vascular stiffening, comorbidity accumulation |
| African ancestry | 3–4× ESRD risk (APOL1 variants) | Genetic (G1/G2 variants); HIV-associated nephropathy |
| Male sex | 1.5× faster progression | Hormonal, behavioral, healthcare access factors |
| Obesity | Independent risk factor | Hyperfiltration, RAAS activation, inflammation |
| Smoking | Accelerates progression | Vascular injury, oxidative stress |
KDIGO Staging (GFR + Albuminuria)
Combined staging (G1–G5 × A1–A3) predicts progression and CVD risk better than GFR alone. Example: G3aA2 (GFR 45–59, ACR 30–300) has higher risk than G3aA1.
Clinical Presentation (Often Late)
- Fatigue, anorexia, nausea, pruritus (uremic toxins)
- Volume overload: edema, hypertension, pulmonary congestion
- Mineral bone disorder: hyperphosphatemia, secondary HPT, vascular calcification
- Anemia: EPO deficiency → Hb <11 g/dL
- Metabolic acidosis: ↓ HCO₃⁻ → muscle catabolism, bone buffering
- Cognitive impairment, neuropathy, sexual dysfunction
Evidence-Based Management Pillars
- Blood pressure control: Target <130/80 (KDIGO 2021); ACEi/ARB first-line (renoprotection + antiproteinuric); avoid dual RAAS blockade
- Glycemic control: HbA1c ∼7% (individualized); SGLT2 inhibitors (empagliflozin, dapagliflozin) — cardiorenal benefit independent of glucose
- SGLT2 inhibitors: Landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) — ↓ CKD progression, CVD events, death in diabetic AND non-diabetic CKD
- Lipid management: Statin ± ezetimibe for age ≥50; LDL target <70 mg/dL
- Dietary: Protein 0.8 g/kg/d (non-dialysis); sodium <2 g/d; potassium individualized; plant-dominant diet
- Acidosis correction: Oral bicarbonate if HCO₃⁻ <22 mmol/L
- Anemia management: ESA if Hb <10 g/dL; iron repletion first (TSAT >20%, ferritin >100)
- Mineral bone disorder: Phosphate binders, vitamin D analogs, calcimimetics per KDIGO
- Renal replacement planning: Pre-emptive transplant > home dialysis (PD/HHD) > in-center HD; vascular access early
Emerging Therapies
- Non-steroidal MRA (finerenone) — FIDELIO/DIAFIGO trials
- Endothelin antagonists (avrasentan) — glomerular protection
- Anti-fibrotics, HIF-PH inhibitors (oral EPO)
CKD is a cardiovascular risk multiplier. Early detection (screening high-risk), SGLT2 inhibitor initiation, and multidisciplinary nephrology care alter the trajectory from inevitable decline to manageable chronic disease.
Kidney Disease - Related Articles
- Understanding and Managing Chronic Kidney Failure Symptoms
- Renovascular Disease: Causes, Symptoms & Risk Factors
- Understanding Kidney Damage: Causes, Repair Options & Treatment
- CT Scans for Polycystic Kidney Disease: Understanding the Role
- Chronic Kidney Disease: Global Burden, Risk Stratification, and Multimodal Management
- Acquired Kidney Absence: Causes, Diagnosis, and Long-Term Management
- Urine Volume and Color: Physiologic and Pathologic Determinants
